Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7851624 in Relapsed/Refractory Multiple Myeloma
NCT07558915Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Jun 2026
- Primary completion
- Jul 2030
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RO7851624 in multiple myeloma (MM), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events at 2 years. Started Jun 2026; status: recruiting.
02
Drugs
RO7851624
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07558915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558915.